Drug · CHEMBL1607
TOPOTECAN HYDROCHLORIDE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. TOPOTECAN HYDROCHLORIDE. Drugs and targets, record CHEMBL1607. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1607
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Evotopin, Hycamtin, Potactasol, Topotecan actavis, Topotecan eagle, Topotecan hospira, Topotecan teva
- ChEMBL
- Other names
Evotopin, NSC-759263, Nogitecan hydrochloride, SK&F S-104864-A, SK&F-S-104864-A, SK&F-S-104864A, SK-S-104864-A, Topotecan (as hydrochloride), Topotecan actavis, Topotecan hcl, Topotecan hospira, Topotecan teva
- ChEMBL
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| TOP1 | DNA topoisomerase 1 | DNA topoisomerase I inhibitor | INHIBITOR | https://conductscience.org/library/genes/7150 |
Source ChEMBL
Diseases47
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 47Source Open Targets
See all 47 diseasesTrials106
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00011986 | Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer | Phase 3 | 4,312 | 2016-04-19 | topotecan hydrochloride | Its name | ClinicalTrials.gov |
| NCT00567567 | Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma | Phase 3 | 665 | 2017-06-27 | topotecan hydrochloride | Its name | ClinicalTrials.gov |
| NCT01231906 | Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma | Phase 3 | 642 | 2021-05-04 | topotecan hydrochloride | Its name | ClinicalTrials.gov |
| NCT00499616 | Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma | Phase 3 | 464 | 2017-06-27 | topotecan hydrochloride | Its name | ClinicalTrials.gov |
| NCT00803062 | Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer | Phase 3 | 452 | 2016-05-24 | topotecan hydrochloride | Its name | ClinicalTrials.gov |
| NCT00828139 | S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer | Phase 2 | 189 | 2016-04-04 | topotecan hydrochloride | Its name | ClinicalTrials.gov |
| NCT02357810 | Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas | Phase 2 | 178 | 2020-08-10 | topotecan hydrochloride | Its name | ClinicalTrials.gov |
| NCT01798004 | Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | Phase 1 | 150 | 2017-02-09 | topotecan hydrochloride | Its name | ClinicalTrials.gov |
| NCT01175356 | Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin | Phase 1 | 99 | 2017-09-28 | topotecan hydrochloride | Its name | ClinicalTrials.gov |
| NCT01012817 | Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer | Phase 1/2 | 88 | 2023-07-19 | topotecan hydrochloride | Its name | ClinicalTrials.gov |
1 to 10 of 106
See all 106 trialsComparisons in its trials11
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm A (Combination Chemotherapy) vs Arm B (Combination Chemotherapy, Topotecan Hydrochloride): deaths from any cause | 51 of 308 | 42 of 318 | 626 | NCT01231906 | Trial comparisons |
| Arm A (Combination Chemotherapy) vs Arm B (Combination Chemotherapy, Topotecan Hydrochloride): serious adverse events | 8 of 308 | 11 of 318 | 626 | NCT01231906 | Trial comparisons |
| Ziv-aflibercept + Topotecan vs Topotecan: serious adverse events | 44 of 92 | 17 of 87 | 179 | NCT00828139 | Trial comparisons |
| Regimen I vs Regimen II: serious adverse events | 8 of 15 | 10 of 65 | 80 | NCT00114166 | Trial comparisons |
| Arm A: Topotocan vs Arm B: OS-906: serious adverse events | 7 of 14 | 18 of 28 | 42 | NCT01533181 | Trial comparisons |
| CAELYX vs Topotecan Hydrocloride (HCl): Number of Participants With Progression-free Survival Incidence at Week 24 | 6 of 14 | 2 of 12 | 26 | NCT01840943 | Trial comparisons |
| CAELYX vs Topotecan Hydrocloride (HCl): serious adverse events | 1 of 14 | 1 of 12 | 26 | NCT01840943 | Trial comparisons |
| Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) vs Arm B (Topotecan Hydrochloride, Carboplatin): Number of Participants Still Alive at Study Completion | 5 of 16 | 5 of 9 | 25 | NCT03289910 | Trial comparisons |
| Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) vs Arm B (Topotecan Hydrochloride, Carboplatin): deaths from any cause | 11 of 16 | 4 of 9 | 25 | NCT03289910 | Trial comparisons |
| Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin) vs Arm B (Topotecan Hydrochloride, Carboplatin): Number of Participants Without Disease at Study Completion | 3 of 16 | 3 of 9 | 25 | NCT03289910 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials58
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1607
GET https://conductscience.org/api/drugs/v1/CHEMBL1607/diseases?page=2